MHUA vs. PAVM, NEPH, LYRA, PYPD, GCTK, TTOO, NXGL, MBOT, SSKN, and PETV
Should you be buying Meihua International Medical Technologies stock or one of its competitors? The main competitors of Meihua International Medical Technologies include PAVmed (PAVM), Nephros (NEPH), Lyra Therapeutics (LYRA), PolyPid (PYPD), GlucoTrack (GCTK), T2 Biosystems (TTOO), NEXGEL (NXGL), Microbot Medical (MBOT), STRATA Skin Sciences (SSKN), and PetVivo (PETV). These companies are all part of the "surgical & medical instruments" industry.
Meihua International Medical Technologies (NASDAQ:MHUA) and PAVmed (NASDAQ:PAVM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, community ranking, earnings, profitability, risk, media sentiment and valuation.
Meihua International Medical Technologies has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, PAVmed has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.
Meihua International Medical Technologies has higher revenue and earnings than PAVmed.
In the previous week, PAVmed had 6 more articles in the media than Meihua International Medical Technologies. MarketBeat recorded 6 mentions for PAVmed and 0 mentions for Meihua International Medical Technologies. PAVmed's average media sentiment score of 0.56 beat Meihua International Medical Technologies' score of 0.00 indicating that PAVmed is being referred to more favorably in the news media.
PAVmed has a consensus price target of $21.00, indicating a potential upside of 1,073.18%. Given PAVmed's higher probable upside, analysts plainly believe PAVmed is more favorable than Meihua International Medical Technologies.
PAVmed received 201 more outperform votes than Meihua International Medical Technologies when rated by MarketBeat users.
1.2% of Meihua International Medical Technologies shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 66.6% of Meihua International Medical Technologies shares are owned by company insiders. Comparatively, 12.6% of PAVmed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Meihua International Medical Technologies has a net margin of 0.00% compared to PAVmed's net margin of -2,037.67%.
Summary
PAVmed beats Meihua International Medical Technologies on 8 of the 13 factors compared between the two stocks.
Get Meihua International Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for MHUA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MHUA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Meihua International Medical Technologies Competitors List
Related Companies and Tools
